Lilly To Offer Direct-To-Employer Programs
Eli Lilly and Co. is preparing a new direct-to-employer model that will allow companies to offer coverage for its obesity medications, including Zepbound, beginning in early 2026.
Read MoreTag Archives: Weight Loss
Lilly Shares Slide Following Weight Loss Pill Trial Results
Indianapolis-based Eli Lilly and Co. shares fell Thursday, Aug. 7 following the pharmaceutical company’s second-quarter earnings report, alongside results from a closely watched trial of its experimental weight-loss pill.
Read More
New Weight-Loss Drug Announces Positive Results of Human Adipose Tissue Study
Adipo Therapeutics, LLC, a late pre-clinical biopharmaceutical company developing treatments for obesity and related metabolic disorders, announced the positive results for a key study demonstrating promising results using human tissue samples.
Read More